[药物重新定位及其在临床糖尿病学的方面]
Bence Pokoly1,2, Anikó Somogyi3
11 Országos Mozgásszervi Intézet - Országos Reumatológiai és Fizioterápiás Intézet Budapest, Frankel Leó út 25-29., 1023 Magyarország.
Orvosi hetilap
|December 8, 2024
概括
药物重新定位将现有药物重新用于新的医疗用途,提供了优势和潜在的挑战. 本综述探讨了成功的应用,包括现在用于糖尿病的抗糖尿病药物,因为它们的降血糖作用.
科学领域:
- 药理学 药理学 是一个学科.
- 药物开发 药物开发
- 医学化学 医学化学
背景情况:
- 药物重新定位是制药开发中的有效策略.
- 它涉及对现有药物确定新的治疗指示.
- 这种方法可以加速药物开发时间表并降低成本.
研究的目的:
- 提供药物重新定位过程的概述.
- 讨论药物重新定位的优势和潜在的陷.
- 检查重新定位药物的成功应用,特别是在糖尿病治疗中.
主要方法:
- 关于药物重新定位策略的文献综述.
- 对重新使用药物的案例研究进行分析.
- 检查药理学数据的血糖降低特性.
主要成果:
- 药物重新定位在药物开发中提供了显著的好处.
- 最初针对其他疾病开发的几种药物在治疗糖尿病中发现了新的用途.
- 某些药物的已知的降血糖效应导致它们被重新定位为糖尿病治疗.
结论:
- 药物重新定位是一种有价值的方法,在制药研究中越来越多地被采用.
- 该审查强调了糖尿病管理中药物重用成功的例子.
- 了解现有药物的药理性质可以打开新的治疗机会.
相关概念视频
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
Oral Hypoglycemic Agents: Biguanides and Glitazones
183
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
183
Oral Hypoglycemic Agents: Glinides
147
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
147
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K


